Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002231 | Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers | PHASE1 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 1 | United States |
| NCT00002232 | A Study of GENEVAX-HIV, a Possible Vaccine | PHASE1 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| APL 400-003 | BIOLOGICAL | - |
Inclusion Criteria You may be eligible for this study if you: * Are 18 - 60 years old. * Are HIV-negative and in good health. * Are able to understand how infections such as HIV are spread. * Agree to use effective methods of birth control during the study. Exclusion Criteria You will not be eli...